Cargando…
Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
We aimed to explore the value of contrast-enhanced ultrasound (CEUS) in early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS) in locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NAC). LABC patients who underwent CEUS before and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378059/ https://www.ncbi.nlm.nih.gov/pubmed/37510121 http://dx.doi.org/10.3390/diagnostics13142378 |
_version_ | 1785079671983964160 |
---|---|
author | Wan, Caifeng Zhou, Liheng Li, Hongli Wang, Lin Li, Fenghua Yin, Wenjin Wang, Yaohui Jiang, Lixin Lu, Jinsong |
author_facet | Wan, Caifeng Zhou, Liheng Li, Hongli Wang, Lin Li, Fenghua Yin, Wenjin Wang, Yaohui Jiang, Lixin Lu, Jinsong |
author_sort | Wan, Caifeng |
collection | PubMed |
description | We aimed to explore the value of contrast-enhanced ultrasound (CEUS) in early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS) in locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NAC). LABC patients who underwent CEUS before and during NAC from March 2014 to October 2018 were included and assessed. Logistic regression analysis and the Cox proportional hazards model were used to identify independent variables associated with pCR and RFS. Among 122 women, 44 underwent pCR. Molecular subtype, peak intensity (PEAK) and change in diameter were independent predictors of pCR after one cycle of NAC (area under the receiver operating characteristic curve [AUC], 0.81; 95% CI: 0.73, 0.88); Molecular subtype, PEAK and change in time to peak (TTP) were independently associated with pCR after two cycles of NAC (AUC, 0.85; 95% CI: 0.77, 0.91). A higher clinical T (hazard ratio [HR] = 4.75; 95% CI: 1.75, 12.87; p = 0.002) and N stages (HR = 3.39; 95% CI: 1.25, 9.19; p = 0.02) and a longer TTP (HR = 1.06; 95% CI: 1.01, 1.11; p = 0.02) at pre-NAC CEUS were independently associated with poorer RFS. CEUS can be used as a technique to predict pCR and RFS early in LABC patients treated with NAC. |
format | Online Article Text |
id | pubmed-10378059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103780592023-07-29 Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer Wan, Caifeng Zhou, Liheng Li, Hongli Wang, Lin Li, Fenghua Yin, Wenjin Wang, Yaohui Jiang, Lixin Lu, Jinsong Diagnostics (Basel) Article We aimed to explore the value of contrast-enhanced ultrasound (CEUS) in early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS) in locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy (NAC). LABC patients who underwent CEUS before and during NAC from March 2014 to October 2018 were included and assessed. Logistic regression analysis and the Cox proportional hazards model were used to identify independent variables associated with pCR and RFS. Among 122 women, 44 underwent pCR. Molecular subtype, peak intensity (PEAK) and change in diameter were independent predictors of pCR after one cycle of NAC (area under the receiver operating characteristic curve [AUC], 0.81; 95% CI: 0.73, 0.88); Molecular subtype, PEAK and change in time to peak (TTP) were independently associated with pCR after two cycles of NAC (AUC, 0.85; 95% CI: 0.77, 0.91). A higher clinical T (hazard ratio [HR] = 4.75; 95% CI: 1.75, 12.87; p = 0.002) and N stages (HR = 3.39; 95% CI: 1.25, 9.19; p = 0.02) and a longer TTP (HR = 1.06; 95% CI: 1.01, 1.11; p = 0.02) at pre-NAC CEUS were independently associated with poorer RFS. CEUS can be used as a technique to predict pCR and RFS early in LABC patients treated with NAC. MDPI 2023-07-14 /pmc/articles/PMC10378059/ /pubmed/37510121 http://dx.doi.org/10.3390/diagnostics13142378 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wan, Caifeng Zhou, Liheng Li, Hongli Wang, Lin Li, Fenghua Yin, Wenjin Wang, Yaohui Jiang, Lixin Lu, Jinsong Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer |
title | Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer |
title_full | Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer |
title_fullStr | Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer |
title_full_unstemmed | Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer |
title_short | Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer |
title_sort | multiparametric contrast-enhanced ultrasound in early prediction of response to neoadjuvant chemotherapy and recurrence-free survival in breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378059/ https://www.ncbi.nlm.nih.gov/pubmed/37510121 http://dx.doi.org/10.3390/diagnostics13142378 |
work_keys_str_mv | AT wancaifeng multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer AT zhouliheng multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer AT lihongli multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer AT wanglin multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer AT lifenghua multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer AT yinwenjin multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer AT wangyaohui multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer AT jianglixin multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer AT lujinsong multiparametriccontrastenhancedultrasoundinearlypredictionofresponsetoneoadjuvantchemotherapyandrecurrencefreesurvivalinbreastcancer |